259 related articles for article (PubMed ID: 23357858)
1. Tolerogenic vaccines for Multiple sclerosis.
Mannie MD; Curtis AD
Hum Vaccin Immunother; 2013 May; 9(5):1032-8. PubMed ID: 23357858
[TBL] [Abstract][Full Text] [Related]
2. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
3. IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.
Wang D; Ghosh D; Islam SM; Moorman CD; Thomason AE; Wilkinson DS; Mannie MD
J Immunol; 2016 Oct; 197(8):2992-3007. PubMed ID: 27619998
[TBL] [Abstract][Full Text] [Related]
4. Steroid-Peptide Immunoconjugates for Attenuating T Cell Responses in an Experimental Autoimmune Encephalomyelitis Murine Model of Multiple Sclerosis.
Sands RW; Tabansky I; Verbeke CS; Keskin D; Michel S; Stern J; Mooney DJ
Bioconjug Chem; 2020 Dec; 31(12):2779-2788. PubMed ID: 33284575
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.
Mannie MD; Blanchfield JL; Islam SM; Abbott DJ
Front Immunol; 2012; 3():255. PubMed ID: 22934095
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for multiple sclerosis: progress to date.
Correale J; Farez M; Gilmore W
CNS Drugs; 2008; 22(3):175-98. PubMed ID: 18278975
[TBL] [Abstract][Full Text] [Related]
7. Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).
Abbott DJ; Blanchfield JL; Martinson DA; Russell SC; Taslim N; Curtis AD; Mannie MD
BMC Immunol; 2011 Dec; 12():72. PubMed ID: 22208499
[TBL] [Abstract][Full Text] [Related]
8. DNA-based vaccines for multiple sclerosis: current status and future directions.
Fissolo N; Montalban X; Comabella M
Clin Immunol; 2012 Jan; 142(1):76-83. PubMed ID: 21163708
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.
Derdelinckx J; Mansilla MJ; De Laere M; Lee WP; Navarro-Barriuso J; Wens I; Nkansah I; Daans J; De Reu H; Jolanta Keliris A; Van Audekerke J; Vanreusel V; Pieters Z; Van der Linden A; Verhoye M; Molenberghs G; Hens N; Goossens H; Willekens B; Cras P; Ponsaerts P; Berneman ZN; Martínez-Cáceres EM; Cools N
J Neuroinflammation; 2019 Aug; 16(1):167. PubMed ID: 31416452
[TBL] [Abstract][Full Text] [Related]
10. T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.
O'Brien K; Gran B; Rostami A
Immunotherapy; 2010 Jan; 2(1):99-115. PubMed ID: 20231863
[TBL] [Abstract][Full Text] [Related]
11. Antigen-specific T cells in autoimmune diseases with a focus on multiple sclerosis and experimental allergic encephalomyelitis.
Xiao BG; Link H
Cell Mol Life Sci; 1999 Oct; 56(1-2):5-21. PubMed ID: 11213261
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis.
Cappellano G; Woldetsadik AD; Orilieri E; Shivakumar Y; Rizzi M; Carniato F; Gigliotti CL; Boggio E; Clemente N; Comi C; Dianzani C; Boldorini R; Chiocchetti A; Renò F; Dianzani U
Vaccine; 2014 Sep; 32(43):5681-9. PubMed ID: 25149432
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with autologous dendritic cells: from experimental autoimmune encephalomyelitis to multiple sclerosis.
Link H; Huang YM; Masterman T; Xiao BG
J Neuroimmunol; 2001 Mar; 114(1-2):1-7. PubMed ID: 11240009
[TBL] [Abstract][Full Text] [Related]
14. A Tolerogenic Artificial APC Durably Ameliorates Experimental Autoimmune Encephalomyelitis by Directly and Selectively Modulating Myelin Peptide-Autoreactive CD4
Wan X; Pei W; Shahzad KA; Zhang L; Song S; Jin X; Wang L; Zhao C; Shen C
J Immunol; 2018 Aug; 201(4):1194-1210. PubMed ID: 29987163
[TBL] [Abstract][Full Text] [Related]
15. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance.
Nguyen TL; Choi Y; Im J; Shin H; Phan NM; Kim MK; Choi SW; Kim J
Nat Commun; 2022 Dec; 13(1):7449. PubMed ID: 36460677
[TBL] [Abstract][Full Text] [Related]
17. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies.
Martin R
J Neural Transm Suppl; 1997; 49():53-67. PubMed ID: 9266414
[TBL] [Abstract][Full Text] [Related]
18. ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis.
Phan NM; Nguyen TL; Shin H; Trinh TA; Kim J
ACS Nano; 2023 Dec; 17(24):24696-24709. PubMed ID: 38051295
[TBL] [Abstract][Full Text] [Related]
19. Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance.
Zhou Y; Leng X; Luo S; Su Z; Luo X; Guo H; Mo C; Zou Q; Liu Y; Wang Y
J Immunol Res; 2016; 2016():5021537. PubMed ID: 28070525
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide plays a key role in the suppressive activity of tolerogenic dendritic cells.
Verinaud L; Issayama LK; Zanucoli F; de Carvalho AC; da Costa TA; Di Gangi R; Bonfanti AP; Ferreira IT; de Oliveira AL; Machado DR; Thomé R
Cell Mol Immunol; 2015 May; 12(3):384-6. PubMed ID: 25308751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
